MedTrace Logo

A Real-world Study of the Safety and Efficacy of Surufatinib in the Treatment of Biliary Tract Carcinoma

NCT05064852 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2021-10-01

No results posted yet for this study

Summary

This is a prospective, single-arm, open-label,multi-center, observational real-world clinical study to observe and evaluate the efficacy and safety of Surufatinib in the treatment of patients with biliary tract cancer (BTC).

Conditions

  • Biliary Tract Carcinoma

Interventions

DRUG

Surufatinib

The study is a real-world study. According to the actual medical history of patients, the usage of Surufatinib was collected.

Sponsors & Collaborators

  • Qilu Hospital of Shandong University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-09-20
Primary Completion
2022-12-20
Completion
2023-12-20

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05064852 on ClinicalTrials.gov